FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Sacks Natalie (Last) (First) (Middle) C/O ADURO BIOTECH, INC.				3. E	2. Issuer Name and Ticker or Trading Symbol ADURO BIOTECH, INC. [ADRO] 3. Date of Earliest Transaction (Month/Day/Year) 09/12/2018									tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify below) Chief Medical Officer			Owner (specify	
740 HEIN (Street) BERKEL (City)	RKELEY CA 94710			-	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line) X	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	e I - N	lon-Deriv	vative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ially	Owne	ed		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				Execution Date,					Acquired (A) or f (D) (Instr. 3, 4 an		d 5) Secu Bene		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(111311. 4)
Common Stock 09/12/20				2018	18			A		87,200(1)	A	\$0	\$0.00		76,748	D		
Common Stock 09/13/20			2018	18		S ⁽²⁾		3,028	D	\$6.4993(3)		1	73,720	D				
		Та	ble II								osed of, convertib				vned			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		on Date (Month/Day/Year)	Execut if any			action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)		Deri Seci (Inst		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	or Number of Shares					

Explanation of Responses:

- 1. Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018.
- 2. The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.25 to \$6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

/s/ Jennifer Lew, Attorney-in-09/14/2018

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.